"threshold responses to goitrin were associated with responses to both PROP (P = 8.9 x 10(-4); r(s) = 0.46) and PTC (P = 7.5 x 10(-4); r(s) = 0.46)... goitrin responses were significantly associated with mutations in TAS2R38 (P = 9.3 x 10(-3)), but the same mutations accounted for a smaller proportion of variance in goitrin response (r(2) = 0.16) than for PROP (r(2) = 0.50) and PTC (r(2) = 0.57)."
逐語: 'Functional expression studies demonstrate that five different haplotypes from the hTAS2R38 gene code for operatively distinct receptors.' PAV 受容体は EC50 1.1 uM（PTC）および 2.1 uM（PROP）で応答した一方、'hTAS2R38-AVI did not respond to PTC or PROP concentrations as high as 1 mM' だった。PVI、AAI、AAV は PAV に近い EC50 で応答した。濃度-強度関数と認知閾値は TAS2R38 ダイプロタイプ既知の被験者32名で測定され、ある PAV 被験者の弁別可能な最低濃度は PAV 受容体の in vitro EC50 と対応していた。
文脈: Eib et al. (2020) の全文Discussionが、シニグリンの苦味とTAS2R38の関係について言及: 逐語「Sinigrin is associated with bitterness; this is a basic taste, which is predominantly perceived via the TASTE 2 receptor (TAS2R) family on the tongue (Bell et al., 2018). In particular, sinigrin binds preferably to TAS2R38 (Meyerhof, Kuhn, Chudoba, et al., 2010).」これはEib自身の測定ではなく、Meyerhof et al. 2010の受容体選好性の知見を引用した二次的言及である。
文脈: 試験管内では、作動薬ごとの EC50 のアレル間差は統計的に有意でなかった一方、同じ作動薬内での応答の大きさ（ΔF/F）はアレル間で大きく異なった。PAV は全作動薬に高く応答し、AVI はどれにも基線を超えて応答しなかった。 逐語: 「allelic differences in EC50 within agonists were not statistically significant. In contrast, within-agonist comparisons revealed highly divergent functionality among alleles as measured by ΔF/F.」
"goitrin elicits a weaker response from the sensitive (PAV) allele of TAS2R38 (EC(50) = 65.0 microM) than do either PROP (EC(50) = 2.1 microM) or PTC (EC(50) = 1.1 microM) and no response at all from the insensitive (AVI) allele."
